Equipment & Inventory Checklist

A hyperbaric oxygen therapy equipment business stands or falls on how it sources, stocks and services hardware. Before you write a single financial line, decide which of three models you are actually running: a distributor/reseller moving chambers and parts, a leasing operator placing units in clinics on monthly terms, or a treatment operator that owns chambers and bills sessions. Each carries a different inventory list. The checklist below covers the full kit a serious operator needs, with the price bands you should plug into your own model rather than the round numbers competitors quote.

Core chamber inventory

• Clinical monoplace chambers, single-patient acrylic or steel units, $25,000-$100,000 each. The volume seller for wound-care clinics and independent wellness sites.
• Multiplace medical units, walk-in steel chambers treating several patients at once, $150,000-$500,000+. Long sales cycle, hospital and large-clinic buyers only.
• Soft / mild home chambers, fabric, low-pressure units, $3,500-$15,000. High volume, low margin, and a regulatory minefield if marketed as clinical HBOT.
• Replacement acrylic, gaskets and seals, recurring consumable revenue; budget a parts float of $8,000-$25,000.

Oxygen, safety and ancillary kit

• Oxygen concentrators or bulk O₂ supply with regulators and fire-rated storage, non-negotiable for clinical pressure.
• Fire-suppression and grounding systems, the FDA has issued provider warnings about fire risk; this is a build-out line, not an optional extra.
• Patient monitoring and communication, intercoms, transcutaneous oximetry, ECG pass-throughs for medical settings.
• Calibration and servicing tools, your service contracts are a margin engine; stock the diagnostic kit to support them.
• Delivery, rigging and installation gear, multiplace units need crane access and certified installers.

The single biggest planning mistake here is treating a soft chamber and a cleared monoplace chamber as interchangeable inventory. They sell to different buyers, carry different liability, and one of them cannot legally be marketed for the conditions the other is cleared to treat. Your inventory plan should keep those product lines, and their margins, separate from page one.

Picking the right model before you spend a penny

The three models are not just labels; they change your balance sheet, your tax treatment and the kind of lender who will back you. A pure distributor carries inventory and books revenue at the point of sale, so cash flow is lumpy and tied to deal closes. A leasing operator capitalises the chambers as assets and earns smoother monthly income, which reads better to a bank but ties up capital up front. A treatment operator takes on the heaviest fixed cost, the clinical-staffing and the reimbursement complexity, in exchange for the highest revenue per chamber. Most successful operators in this niche eventually run a hybrid, but a first plan should commit to a lead model and treat the others as Year 2 or Year 3 expansion. Stating that sequencing explicitly is one of the fastest ways to make a plan read as credible rather than scattergun.

Whichever model leads, the plan should answer four concrete questions a buyer or lender will ask within the first meeting: where does the hardware come from and on what terms, what happens to a chamber if a clinic customer defaults, how is oxygen sourced and stored safely, and who installs and services the units in the field. A plan that answers those four in plain numbers is already ahead of most of the competition, which tends to stop at a market-size paragraph and a wishful revenue chart. Investors fund operators who have clearly thought through the boring, expensive parts of the business, and in this niche the boring parts, oxygen safety, installation logistics and asset recovery, are precisely where the money and the risk live.

What It Costs to Launch

Plan for $90,000 to $750,000 in the United States, or roughly £70,000 to £590,000 in the United Kingdom, with the spread driven almost entirely by which business model and chamber class you choose. A lean reseller stocking soft chambers and a couple of monoplace units sits near the floor. A treatment clinic building a fire-rated multiplace suite sits near the ceiling, and a full hospital-grade clinic can run far higher still, with one industry estimate putting a large clinical build at over $12M in CAPEX where chambers and build-out make up about 75% of the spend (Financial Models Lab, 2025).

Cost breakdown

• Opening chamber inventory: $40,000-$300,000 (£32K-£240K) depending on monoplace vs multiplace mix
• Facility lease, fit-out & fire-rated room: $50,000-$200,000 (£40K-£160K) for an operator; minimal for a pure distributor
• Oxygen handling, safety & installation kit: $10,000-$40,000 (£8K-£32K)
• Accreditation & clinical compliance (UHMS / IHA): $8,000-$12,000 in the US per Hyperbaric Business Solutions, 2025
• Insurance, product liability & legal: $5,000-$20,000/yr (£4K-£15K)
• Marketing & sales (10-20% of budget): $15,000-$80,000 (£12K-£64K)
• Working capital (3-6 months): $20,000-$90,000 (£16K-£72K)

Funding routes

In the US, an SBA 7(a) loan (up to $5M, terms to 25 years) is the standard route for an equipment business with real collateral in the chambers themselves; an SBA 504 loan can fund the real-estate and fixed-asset side of a clinic build. Equipment-finance lines and vendor leasing are common because the hardware secures the loan. Our bespoke plan service builds the SBA-compliant projections lenders expect. In the UK, the government-backed Start Up Loan offers up to £25,000 per founder at 6% fixed with free mentoring, and asset-finance lenders will lease against the chambers. Comparable schemes exist in Canada (BDC), Australia (NAB asset finance) and the UAE (Khalifa Fund).

One funding angle most operators miss: because a monoplace chamber holds its value and can be repossessed and re-leased, lenders treat a leasing book far more favourably than a pure inventory loan. A plan that shows a lease portfolio with residual values attached usually wins better terms than one that just asks for stock finance.

Chamber Makers & Suppliers

Your supplier relationships are the moat. Distribution rights, service training and parts access decide whether you can win clinical buyers or are stuck reselling soft chambers on price. These are the names that come up most often in the US and UK markets, with the role each tends to play:

• Perry Baromedical, over 60 years of manufacturing and the only full-line maker covering both monoplace (Sigma 34, 36 and 40) and multiplace systems; the anchor brand for clinical buyers (Perry Baromedical).
• Sechrist Industries, a comprehensive monoplace clinical line, known for low-profile gurneys and standard one-year warranties.
• OxyHealth, the dominant name in portable and soft chambers with tamper-proof redundant pressure regulators; the high-volume wellness end.
• Airvida Chambers, a direct-to-business supplier publishing operator startup guidance, useful as a reseller channel and competitive benchmark.
• Hyperbaric Store / Hyperbaric Business Solutions, aggregator and operating-services players worth studying for pricing and bundled-service strategy.

When you map suppliers in your plan, do not stop at a logo grid. Note who grants exclusive territory, who funds service training, lead times on multiplace builds (often months), and warranty terms, because those operational facts decide your real gross margin. A reseller with a Perry service certification and an OxyHealth distribution agreement is a very different credit risk to one buying grey-market soft chambers, and a lender can tell the difference.

The competitive picture sits in three layers. Direct competitors are other regional distributors and the manufacturers' own direct-sales teams. Scaled competitors are national equipment groups with procurement power and existing hospital framework agreements. Substitutes are the cheap import soft-chamber sellers flooding online marketplaces, who compete purely on price and ignore the clinical segment. Your plan should be explicit that you are not trying to beat the import sellers on price; you are winning the clinical and licensed-wellness buyer on service, financing terms, compliance support and uptime. That positioning is what protects margin, and it is the single judgement most weak plans get wrong by chasing the lowest-price segment where there is no profit to defend.

Winning Customers

Hyperbaric equipment is a considered, high-ticket purchase with a long sales cycle, so the go-to-market plan looks nothing like consumer retail. Your buyers are wound-care directors, podiatrists, physiotherapists, sports-recovery clinics and licensed wellness operators, and they buy on three things: clinical credibility, total cost of ownership, and how quickly a broken chamber gets back into service. A plan that treats marketing as "we will run some ads" will not convince anyone who knows the category.

Channels that actually convert

• Direct clinical sales, a named rep working a territory of wound-care and podiatry practices, is still the backbone of clinical chamber sales.
• Referral and accreditation networks, UHMS, IHA and the British Hyperbaric Association communities, where reputation travels fast.
• Search and education content, buyers research "monoplace vs multiplace" and "lease vs buy" long before they call; ranking for those terms feeds the pipeline.
• Trade shows and clinical conferences, where multiplace and high-value deals are sourced and demo units pay for themselves.
• Manufacturer co-marketing, riding the brand equity of Perry, Sechrist or OxyHealth where your distribution agreement allows it.

The economics of customer acquisition matter as much as the channel mix. If your blended cost to acquire a clinical buyer is a few thousand dollars and the lifetime value of that account, counting the chamber, the lease, the parts and the service contract, runs into six figures, the plan should say so in numbers. That ratio is exactly what a lender or investor uses to judge whether your growth is fundable or merely hopeful. It is also why the recurring-revenue lines, service and leasing, matter so much: they turn a one-time transaction into an account you keep selling into for years.

Operations: Installation, Service & Uptime

In equipment businesses, the operations plan is where credibility is won or lost, because the buyer's real question is "what happens after the sale". A chamber that sits broken for three weeks costs a clinic real revenue and costs you the relationship. The plan should describe, in operational terms, how a unit gets from your warehouse to a working installation and how it stays running.

The delivery and service workflow

• Pre-sale site survey, confirming floor loading, oxygen supply, fire-rated space, electrical and access for a monoplace or multiplace unit.
• Certified installation and commissioning, pressure testing, leak checks, oxygen-handling sign-off and staff orientation.
• Preventive maintenance contracts, scheduled servicing that protects warranty, safety and your recurring margin.
• Spare-parts float and loan units, so a fault does not strand a clinic; this is the difference between a vendor and a partner.
• End-of-life refurbishment, taking back leased or traded chambers, refurbishing and reselling them into the value segment.

For leasing operators specifically, the operations plan must also cover asset tracking: where every unit is, its condition, its remaining residual value and the repossession process if a customer defaults. That asset register is not back-office housekeeping; it is the collateral schedule a lender will want attached to the loan, and it is what lets you re-lease a returned chamber rather than write it off. Treat it as a core operational system, not an afterthought.

Regulation: FDA, MHRA & Beyond

This is the section that sinks unprepared operators, because the line between a cleared medical claim and an off-label wellness claim is where the legal and reimbursement risk lives. Get it right in the plan and you de-risk the whole business.

United States

• Clinical chambers are Class II medical devices cleared through the FDA 510(k) pathway under Product Code CBF. They are cleared, not "approved" (Intellicure, on FDA clearances).
• The FDA recognises 13 on-label indications including diabetic foot ulcers, carbon monoxide poisoning, decompression sickness, gas gangrene, compromised grafts and radiation injury.
• Marketing a chamber for conditions outside that list is off-label; the FDA has issued a provider letter and a fire-risk warning on unsafe HBOT use (US FDA).
• State facility licensing, oxygen-storage fire codes and, for treatment operators, UHMS or IHA accreditation at roughly $8,000-$12,000.
• Product liability insurance and clear off-label disclaimers on any wellness marketing.

United Kingdom

• Chambers must carry a CE or UKCA mark and be registered with the MHRA under UK MDR 2002 (GOV.UK / MHRA).
• CE marking is accepted in Great Britain until 30 June 2028, after which UKCA becomes mandatory, a hard deadline to build into your sourcing roadmap.
• Manufacturers and importers need ISO 13485 quality management.
• A non-UK manufacturer must appoint a UK Responsible Person to register and act on its behalf.
• Operators should align with British Hyperbaric Association safety guidance for clinical practice.

Other jurisdictions

For the EU, devices need CE marking under EU MDR 2017/745 with an EU Authorised Representative for importers. In Canada, Health Canada requires a Medical Device Establishment Licence (MDEL) for importers and distributors plus a device licence for the chamber class. If your plan touches more than one market, the regulatory section should map clearance status country by country, because a chamber cleared in the US is not automatically sellable in Great Britain or the EU.

How the Money Works

The number that actually drives this business is not the headline chamber price; it is the blend of one-off resale margin and recurring lease or service revenue. Distributors typically run gross resale margins of 20-40% and net 15-30% after overhead. Treatment operators run thinner because fixed facility cost is high, charging $150-$250 per session at independent clinics and $250-$600 at hospital-based programmes (HBOTGuide, 2025), against a real-world course that averages about 26 sessions rather than the textbook 40.

Worked example: a regional distributor with a leasing arm

Suppose you place 18 monoplace chambers a year at an average $48,000 list price and a 28% gross margin. That is roughly $864,000 in resale revenue and about $242,000 of gross profit before overhead. Now layer on a leasing arm of 12 active monoplace units at $3,200 a month, a band well inside the $2,000-$5,000 monthly lease range operators quote, and you add $460,800 of recurring annual revenue at a higher margin because the asset is already on your books. The recurring line is what turns a transactional reseller into a financeable, defensible business.

Worked example: a treatment operator's session math

If your plan leads with the treatment model instead, the arithmetic is different and tighter. Take a two-chamber wellness-and-wound clinic charging $200 a session. At a realistic 26-session average course, each completed patient is worth about $5,200 in revenue. Run 8 active patients per chamber per week across two chambers and the clinic books in the region of $640,000 a year at full utilisation, but utilisation is the whole game: chambers sitting empty still carry rent, oxygen, staffing and finance cost. This is why treatment operators net less than distributors despite higher headline revenue, and why a credible operator plan models occupancy honestly rather than assuming every chair is full from month one.

Additional revenue streams to model across both models: service and calibration contracts (high margin, sticky), consumable parts (acrylic, gaskets, seals), installation and training fees, and used-chamber refurbishment and resale. For treatment operators, only the FDA-cleared indications attract reliable reimbursement. Medicare Part B covers 80% of the approved cost after the 2026 deductible for qualifying conditions, but pays nothing for wellness or anti-ageing sessions, so a cash-pay model has to carry that side of the book. Spelling out which revenue is reimbursed and which is cash-pay is exactly the detail that separates a fundable plan from an optimistic one.

Market Size & Demand

The global hyperbaric oxygen therapy devices market, the equipment segment you actually sell into, was valued at roughly $3.8 billion in 2025 (Coherent Market Insights, 2025), with Future Market Insights (2025) putting it close at $3.83 billion. That is a much more honest planning base than the trillion-dollar "healthcare" figures some templates quote, because it counts chambers and related hardware rather than the entire medical economy.

Growth is steady rather than explosive. Forecasts cluster around 5-6% CAGR: Technavio projects 6% through 2030, Future Market Insights 5.2% to 2035, and Coherent 5.3% to 2032. iHealthcareAnalyst expects the devices market to reach about $6.9 billion by 2034. The demand drivers are real and durable, an ageing population, rising diabetes prevalence (and the diabetic-wound indication that drives clinical demand), and a fast-growing wellness segment buying soft chambers off-label.

The strategic read for an equipment business: clinical demand is regulated, reimbursed and stable, while wellness demand is faster-growing but legally constrained. The operators who win build a plan that serves both without letting the marketing for one contaminate the compliance of the other.

It is also worth being honest in the plan about why the headline growth rate is modest. Hyperbaric equipment is durable; a well-maintained chamber lasts many years, so replacement cycles are slow and the installed base turns over gradually. That is a feature, not a bug, for an equipment business: it means the after-market, service, parts, refurbishment and re-leasing, is a large and durable revenue pool that compounds as the installed base grows. A plan that frames the slow-replacement reality as a recurring-revenue opportunity rather than a growth ceiling reads as written by someone who actually understands the category. Demand is also geographically uneven, concentrated in markets with established wound-care reimbursement and a mature private-wellness segment, so a plan that names its target regions and the clinic density within them is far more convincing than one quoting a single global number.

Five Mistakes That Sink Equipment Startups

Most plans in this niche fail for predictable reasons. Naming these explicitly, and showing how your plan avoids them, is one of the strongest trust signals you can send a lender or investor who has seen the category before.

• Marketing soft chambers as clinical HBOT. Low-pressure fabric chambers are not cleared for the FDA's 13 indications. Blurring that line invites enforcement and voids the credibility of your whole plan.
• Underbudgeting the facility and safety build. Oxygen handling, fire suppression and a fire-rated room are not optional extras; the FDA has warned providers about fire risk for a reason, and skimping here is both dangerous and disqualifying.
• Assuming insurance pays for everything. Medicare and private payers reimburse only the cleared indications. A model built on wellness sessions getting reimbursed will collapse in diligence.
• Ignoring the UK CE-to-UKCA deadline. CE marking is accepted in Great Britain only until 30 June 2028. A sourcing roadmap that does not plan for UKCA leaves your UK inventory unsellable overnight.
• Buying inventory outright when buyers want leases. Cash-tight clinics prefer monthly terms. Tying up capital in stock you cannot move, instead of structuring lease-to-own, is how distributors run out of runway before they reach scale.

More Questions Buyers Ask

Is it better to lease or buy a hyperbaric chamber?

For the clinic on the other side of your sale, leasing a monoplace chamber at $2,000-$5,000 a month cuts the upfront outlay by more than 80% versus an outright purchase, which is why lease-to-own widens your buyer pool. For your own business, a lease book builds the recurring, financeable revenue lenders prize. Model both lines.

How profitable is a hyperbaric oxygen therapy business?

Equipment distribution nets 15-30% after overhead; leasing and service contracts sit above that on margin. Treatment operators run leaner because the facility is a heavy fixed cost spread over a roughly 26-session average course. Profitability is a function of model choice, not the niche itself.

Can I sell soft chambers as medical HBOT?

No. Soft, low-pressure chambers are not cleared for the FDA's clinical indications, and marketing them as clinical HBOT is the fastest route to an enforcement problem. Keep soft-chamber wellness marketing separate from any cleared medical claim.

How long does FDA 510(k) clearance take for a chamber?

If you are manufacturing or importing a new chamber design, a 510(k) submission under Product Code CBF typically runs three to nine months and costs from roughly $12,000 into the tens of thousands once testing is included. Most resellers sell already-cleared devices and avoid this, which your plan should state explicitly.

Sample Business Plan Preview

Here's an extract from a hyperbaric oxygen therapy equipment plan written by our team, so you can see the level of operational and financial detail you'll get:

What's in the Template

Every Avvale business plan template comes pre-structured for your industry. For a hyperbaric oxygen therapy equipment business, that means these sections are built around chambers, clearance and leasing rather than generic boilerplate:

• Executive Summary, your model (distributor, lessor or operator) stated in the first 60 seconds
• Company Overview, legal structure, reseller agreements, and which markets you are cleared to sell into
• Industry Analysis, the $3.8B devices market, 5-6% CAGR, and clinical-vs-wellness demand split
• Customer Analysis, wound-care clinics, podiatry, hospitals and wellness operators, segmented by buying trigger
• Competitor Analysis, Perry, Sechrist, OxyHealth and regional resellers, mapped by territory and service depth
• Regulatory Plan, FDA Product Code CBF, on-label vs off-label, MHRA/UKCA and the 2028 transition
• Operations Plan, sourcing, installation, servicing, lease administration and inventory float
• Financial Forecast, resale margin, recurring lease income and service revenue modelled separately

The optional Financial Forecast add-on (included in our $300/£250 and $1,000/£800 packages) provides a 5-year Excel model with income statement, cash flow, balance sheet, break-even analysis, lease-portfolio schedule and startup capital requirements. You can browse our full library of free business plan templates or jump straight to the industry-specific template.

Frequently Asked Questions